PMID- 33575855
OWN - NLM
STAT- MEDLINE
DCOM- 20210816
LR  - 20210816
IS  - 1432-1335 (Electronic)
IS  - 0171-5216 (Linking)
VI  - 147
IP  - 9
DP  - 2021 Sep
TI  - Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade 
      dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
PG  - 2681-2691
LID - 10.1007/s00432-021-03544-3 [doi]
AB  - PURPOSE: Previous research on the association between proton pump inhibitor (PPI) 
      use and the risk of progression to high-grade dysplasia (HGD)/esophageal 
      adenocarcinoma (EAC) in Barrett's Esophagus (BE) patients has generated 
      inconsistent findings. This meta-analysis was performed to clarify the 
      association. METHODS: We performed a comprehensive search strategy to select 
      relevant studies up to September 2020. Heterogeneity was assessed using the 
      I-squared statistic. Odds ratios (OR) and 95% confidence intervals (CI) were 
      calculated through either fixed-effects or random-effects model. 
      Duration-response was also performed to assess the gain effects of different PPI 
      intake duration. Sensitivity analysis, subgroup analyses, and tests for 
      publication bias or other small-study effects were conducted. RESULTS: Twelve 
      studies with 155,769 subjects were included. The PPI use was associated with the 
      reduced risk of BE progression to HGD/EAC (OR = 0.47, 95% CI = 0.32-0.71). In the 
      duration-response analysis, the estimated OR for decreased risk of HGD/EAC with 
      PPI intake duration of 12 months was 0.81 (95% CI = 0.71-0.91). Sensitivity 
      analysis suggested the results of this meta-analysis were stable. No publication 
      bias was detected. CONCLUSIONS: PPI use is associated with a decreased risk of 
      HGD/EAC in patients with BE. For further investigation, that more well-designed 
      studies are still needed to elucidate the protective effect of PPI usage on BE 
      patients to prevent HGD/EAC.
CI  - (c) 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part 
      of Springer Nature.
FAU - Chen, Yue
AU  - Chen Y
AD  - Department of Clinical Medicine, School of the First Clinical Medicine, Anhui 
      Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, People's Republic 
      of China.
FAU - Sun, Chenyu
AU  - Sun C
AUID- ORCID: 0000-0003-3812-3164
AD  - Internal Medicine, AMITA Health Saint Joseph Hospital Chicago, 2900 N. Lake Shore 
      Drive, Chicago, IL, 60657, USA. drsunchenyu@yeah.net.
FAU - Wu, Yile
AU  - Wu Y
AD  - Department of Epidemiology and Health Statistics, School of Public Health, Anhui 
      Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, People's Republic 
      of China.
FAU - Chen, Xin
AU  - Chen X
AD  - Department of Epidemiology and Health Statistics, School of Public Health, Anhui 
      Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, People's Republic 
      of China.
FAU - Kailas, Sujatha
AU  - Kailas S
AD  - Department of Gastroenterology, AMITA Health Saint Joseph Hospital Chicago, 2900 
      N. Lake Shore Drive, Chicago, IL, 60657, USA.
FAU - Karadsheh, Zeid
AU  - Karadsheh Z
AD  - Department of Gastroenterology, AMITA Health Saint Joseph Hospital Chicago, 2900 
      N. Lake Shore Drive, Chicago, IL, 60657, USA.
FAU - Li, Guangyuan
AU  - Li G
AD  - Community Healthcare System, 901 MacArthur Blvd, Munster, IN, 46321, USA.
FAU - Guo, Zhichun
AU  - Guo Z
AD  - Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Ave, Boston, 
      MA, 02115, USA.
FAU - Yang, Hongru
AU  - Yang H
AD  - Massachusetts College of Pharmacy and Health Sciences, 179 Longwood Ave, Boston, 
      MA, 02115, USA.
FAU - Hu, Lei
AU  - Hu L
AD  - Department of Clinical Medicine, School of the First Clinical Medicine, Anhui 
      Medical University, No. 81 Meishan Road, Hefei, 230032, Anhui, People's Republic 
      of China.
FAU - Zhou, Qin
AU  - Zhou Q
AD  - Radiation Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN, 55905, USA.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
DEP - 20210211
PL  - Germany
TA  - J Cancer Res Clin Oncol
JT  - Journal of cancer research and clinical oncology
JID - 7902060
RN  - 0 (Proton Pump Inhibitors)
RN  - Adenocarcinoma Of Esophagus
SB  - IM
CIN - J Cancer Res Clin Oncol. 2021 Sep;147(9):2801-2802. PMID: 34086128
MH  - Adenocarcinoma/pathology/*prevention & control
MH  - Barrett Esophagus/*drug therapy/pathology
MH  - Disease Progression
MH  - Esophageal Neoplasms/pathology/*prevention & control
MH  - Humans
MH  - Prognosis
MH  - Proton Pump Inhibitors/*therapeutic use
MH  - Risk Assessment/*methods
MH  - Risk Factors
OTO - NOTNLM
OT  - Barrett's esophagus
OT  - Esophageal adenocarcinoma
OT  - High-grade dysplasia
OT  - Meta-analysis
OT  - Proton pump inhibitor
EDAT- 2021/02/13 06:00
MHDA- 2021/08/17 06:00
CRDT- 2021/02/12 06:11
PHST- 2020/11/07 00:00 [received]
PHST- 2021/01/21 00:00 [accepted]
PHST- 2021/02/13 06:00 [pubmed]
PHST- 2021/08/17 06:00 [medline]
PHST- 2021/02/12 06:11 [entrez]
AID - 10.1007/s00432-021-03544-3 [pii]
AID - 10.1007/s00432-021-03544-3 [doi]
PST - ppublish
SO  - J Cancer Res Clin Oncol. 2021 Sep;147(9):2681-2691. doi: 
      10.1007/s00432-021-03544-3. Epub 2021 Feb 11.